Alicanto Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-07-2024
- Paid Up Capital ₹ 0.25 M
as on 05-07-2024
- Company Age 5 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.01 M
as on 05-07-2024
- Revenue 48.65%
(FY 2022)
- Profit 218.10%
(FY 2022)
- Ebitda 269.73%
(FY 2022)
- Net Worth 182.12%
(FY 2022)
- Total Assets -21.83%
(FY 2022)
About Alicanto Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.25 M.
The company currently has active open charges totaling ₹1.01 M.
Atin Arora and Naresh Arora serve as directors at the Company.
- CIN/LLPIN
U36995HR2019PTC079260
- Company No.
079260
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Mar 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Alicanto Drugs Private Limited offer?
Alicanto Drugs Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Ointment, Pharmaceutical Syrup, Ayurvedic,Herbal Products & Medicine, Diabetic Herbal Medicine, Antihistamines, Pharma & Bioanalytical Services.
Who are the key members and board of directors at Alicanto Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atin Arora  | Director | 25-Mar-2019 | Current |
| Naresh Arora | Director | 25-Mar-2019 | Current |
Financial Performance of Alicanto Drugs.
Alicanto Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.65% increase. The company also saw a substantial improvement in profitability, with a 218.1% increase in profit. The company's net worth Soared by an impressive increase of 182.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Alicanto Drugs?
Unlock access to Alicanto Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Alicanto Biotech Private LimitedActive 3 years 5 monthsAtin Arora and Naresh Arora are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 14 Jun 2022 | ₹1.01 M | Open |
How Many Employees Work at Alicanto Drugs?
Unlock and access historical data on people associated with Alicanto Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Alicanto Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Alicanto Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
